Recruiting

Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.

ClinicalTrials.gov IDNCT06753981

PhaseNot Applicable

Enrollment48

SponsorQianfoshan Hospital

Age18 Years – 80 Years

SexALL

I'm interested View official listing

Conditions studied

Arterial Pulmonary Hypertension (PAH)

About this study

Interventions

Drug: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs — Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.

Primary outcomes

Pulmonary Vascular Resistance (PVR) (Up to 3 months)

Eligibility information

Inclusion Criteria: * Consent and sign the informed consent form * Non-low-risk PAH treatment-naive patients Exclusion Criteria: * Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension * Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary * Pregnant or lactating women * Suffering from mental illness or cognitive impairment * PAH patients with concurrent malignant tumors * Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia * Currently participating in other interventional clinical studies * Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.

Study locations

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-15.